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Abstract: Hepatocellular carcinoma (HCC) is one of the most commonly occurring solid tumors globally and is the 
most frequent cause of cancer death in some parts of the world such as China and sub-Saharan Africa and the 
prognosis without treatment is poor . There is an apparent increase in the number of HCC patients in Egypt.  In Egypt 
liver malignancies were the 3
rd
 most common cancer in men and the 6
th
 in women in National Cancer Institute (NCI), 
Cairo University. The male to female ratio in these studies was 4:1 to 5: 1 and the mean age was 50-60 years old. 
Among the various local percutaneous ablative therapies, radio-frequency ablation (RFA) has attracted the greatest 
interest because of its effectiveness and safety in the treatment of small HCCs, with a 3-years survival rate of 62% – 
68%, a treatment-associated morbidity rate of 0%–12%, and a treatment-related mortality rate of 0%–1%. However, 
complete tumor necrosis rate with RFA for tumors larger than 5 cm is less favorable, and local recurrence rate can be 
as high as 20%, even for HCCs smaller than 3.5 cm.  Percutaneous acetic acid injection (PAI) has been used as a 
potential alternative to Percutaneous ethanol injection (PEI) for therapy of small (less than 3 cm) HCC. It is reported 
that it has a strong cytotoxic effect than ethanol. It causes tissue necrosis by the same mechanisms of dehydration and 
protein denaturation. Its low pH induces swelling of the fibers and promotes dissociation of intermolecular collagen. 
The aim of this work was to evaluate the efficacy of combined RFA and PAI compared to PAI alone the 
management of HCC of relatively large size 5-8 cm in diameter. 30 patients with single lesions of HCC measuring 5-
8 cm in diameter were divided into 2 groups, each composed of 15 patients. Each group was subdivided into 2 
subgroups according to the size, group 1a =7 patients (5-6.5 cm in diameter) & group 1b =8 patients (6.6-8 cm) while 
group 2a=8 patients (5-5.6 cm) & group2b=7 patients (6.6-8 cm). Group1 was treated by 2-3 sessions of intralesional 
injection of 6 ml of 50% acetic acid using 21 gauge spinal needle, 1 week apart.  Group2 was treated by one setting 
of RFA using RF needle with that expand on deployment up to 5 cm in diameter plus 2-3 sessions PAI as in group1. 
Complete ablation was achieved in 46.6% of group 2 treated by combination of RFA and 2-3 sessions of PAI, 
compared to 20% of group1 treated by 2-3 sessions of PAI with highly significant difference. Dividing the groups 
into 2 subgroups according to HCC diameter, subgroup a of 5-6.5 cm and subgroup b of 6.6-8 cm in diameter, 
complete ablation was achieved in 62.5% of subgroup 2a compared to 28.5% of subgroup 1a In conclusion 
combination therapy of PAI plus RFA is needed if better ablation is seeked. 
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1. Introduction 
        Hepatocellular carcinoma (HCC) is the fifth 
most common cancer worldwide and the third most 
common cause of cancer-related death (Llovet et al., 
2003). 
       With 500,000 new cases diagnosed yearly. The 
age-adjusted worldwide incidence varies by 
geographic area, increasing from 5.5/100,000 of the 
population in the United States and Europe to 
14.9/100,000 in Asia and Africa (Bosch et al., 1999) 
The higher incidence observed in Europe during 
the past decade probably reflects the increasing 
number of cases of hepatitis C infection (Tanaka et 
al., 2002 and El-Serag et al., 2003) and liver 
cirrhosis, both strong predisposing factors for HCC 
(Colombo, 2003). In most parts of Asia and Africa, 
hepatitis B virus infection is most relevant (Liaw et 
al., 1986). In the West and Japan hepatitis C virus 
infection is the main risk factor (Tsukuma et al., 
1993 and Bruno & Silini., 1999), although patients 
with alcoholic cirrhosis or haemochromatosis are also 
at increased risk (Niederau et al., 1985). Older 
patients are more likely to develop HCC (Colombo, 
2003). In contrast, in developing countries HCC more 
frequently affects younger individuals who have 
chronic hepatitis B (Zhou et al., 2001),  
          In Egypt liver malignancies were the 3
rd
 
most common cancer in men and the 6
th
 in women in 
National Cancer Institute (NCI), Cairo University. Its 
incidence rate, however, has been increasing over the 
last two decades of the 20
th
 century.  Cirrhotic 
patients have a higher risk than non-cirrhotic patients 
with annual HCC incidences 2-6.6% and 0.4% 
respectively. Unfortunately most of our Egyptian 
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patients are discovered late, especially when 
symptoms like persistent pain or deep jaundice or 
even pulging tender epigastric or hypochondrial 
masses are evident. (El-Attar, 2002)  
     Alpha fetoprotein (AFP) is the most widely 
studied screening test used as a tumor marker for 
HCC. A level more than 200 ng/ml is usually 
regarded as diagnostic (Ryder, 2003). 
   The treatment of hepatocellular carcinoma 
depends on the extent of the disease, the presence or 
absence of cirrhosis and the degree of hepatic 
dysfunction (Farmer et al., 1994).  Few therapies are 
currently considered to be able to achieve complete 
tumor ablation (Llovet and Beaugrand, 2003). 
 Radio Frequency Thermal Ablation (RFA) is 
a local ablation technique designed to destroy the 
tumor by heating, in patients with unresectable liver 
tumors. The technique is safe and effective (Azab et 
al., 2007&2008).  
Radiofrequency ablation (RFA) is becoming 
the most commonly used and perhaps most promising 
modality for tumor ablation (Choti, 2000). The 
rationale for RFA of liver tumors is evident (Azab et 
al., 2007). Firstly, this approach often allows for 
greater preservation of uninvolved hepatic 
parenchyma, directing treatment specifically to the 
tumor location. This feature is particularly beneficial 
in patients with hepatocellular carcinoma in the 
background of cirrhosis, where hepatic reserve is 
often limited. In cases of metastatic disease, tumors 
that are multiple, bilobar, centrally located, or in areas 
not technically respectable are potentially well suited 
for this approach (Azab et al., 2007). 
 Percutaneous acetic acid injection (PAI) may 
have good penetration into cancer cells in the tumor 
capsule or intratumoral septa. (Okada, 1999) and it is 
better than ethanol in this respect (Azab et al., 2009) 
Percutaneous acetic acid injection (PAI) has 
been used as a potential alternative to PEI for therapy 
of small (less than 3 cm) HCC. It is reported that it 
has a strong cytotoxic effect than ethanol. It causes 
tissue necrosis by the same mechanisms of 
dehydration and protein denaturation. Its low pH 
induces swelling of the fibers and promotes 
dissociation of intermolecular collagen (Ohnishi et 
al., 1994 and Azab et al., 2007&2009).  
   Moreover, in HCC nodules, injected acetic 
acid may have good penetration into cancer cells in 
the tumor capsule or intratumoral septa, whereas 
ethanol cannot penetrate them. Therefore in PAI, it is 
expected that the number of treatment sessions may 
be reduced and local recurrence rates may decrease as 
compared with PEI. The preliminary reports 
suggested the efficacy of PAI for HCC smaller than 3 
cm; all tumors could be treated successfully with PAI, 
and none of the PAI treated tumors developed local 
recurrence (Okada, 1999). Ohnishi et al. (1998) 
performed a randomized trial comparing PAI with 
PEI conducted in patients with one to four HCC 
nodules smaller than 3 cm. Although all tumors were 
treated successfully by either therapy, local 
recurrence was significantly less common with PAI 
compared with PEI (2 year local recurrence rate, 10% 
vs. 44%). Moreover, PAI showed a more favorable 
prognosis than PEI (2 year survival rate, 92% vs. 
63%). It was found that the capability of 50% AA to 
necrotize hepatocytes is assumed to be more than 3 
times that of absolute ethanol (Ohnishi et al., 1998). 
 
2. Patients and methods 
This study was carried out on 30 patients with 
HCC who attended the Tropical Medicine 
Department Al-Hussein University Hospital from 
December 2010 to October 2011, they were 
diagnosed by imaging techniques including 
abdominal ultrasound that shows focal lesion in 
cirrhotic liver followed by Triphasic spiral C T scan 
which shows early enhancement in the arterial phase 
and rapid washout in the delayed venous phase or by 
elevated alpha fetoprotein beyond the cut off level 
(200 ng /ml) or liver biopsy confirming HCC. 
Inclusion criteria: 
-Presence of a single focal lesion 5-8 cm in diameter. 
-Absence of extra hepatic spread. 
-Absence of portal vein thrombosis.   
- Absence of ascites. 
-Patients should be child A or B according to Child 
Pugh classification. 
-Platelet count should be ≥ 60.000/cmm and 
Prothrombine concentration ≥ 60 %. 
-The patients must be aware of therapy and sign 
consents.  
These patients were classified into two groups: 
Each group was subdivided into 2 subgroups 
according to the size of the tumor,  
Group 1a:-included 7 patients (5-6.5 cm in diameter) 
managed by 2-3 sessions of PAI only, 1 weeks apart 
 Group 1b:-included 8 patients (6.6-8 cm) managed 
by 2-3 sessions of PAI only, 1weeks apart 
 Group 2a:-included 8 patients (5-6.5 cm) treated by 
one setting of RFA using RF needle with that expand 
on deployment up to 5 cm in diameter plus 2-3 
sessions PAI 2 weeks apart. 
Group2b:- included7 patients (6.6-8 cm) treated by 
one setting of RFA using RF needle with that expand 
on deployment up to 5 cm in diameter plus 2-3 
sessions PAI 2 weeks apart. 
N.B We didn’t consider a group for RFA alone 
because we believed that it would be non ethical since 
we know for sure that the  expansion of the RFA 
needle  arrays is limited to 5 cm only leaving upto 3 
cm without ablation since we have lesions upto 8 cm 
Journal of American Science 2013;9(6)                                             http://www.jofamericanscience.org 
- 624 - 
in diameter. In case of Acetic Acid we thought that it 
may diffuse to distant tissues covering the whole 
lesion if not the most of it.For this reason we used a 
group of PAI and for RFA. 
All patients had given their informed consent 
to the study and were evaluated as follows.1) Full 
history: with special stress on recent abdominal 
swelling, abdominal pain, and loss of weight or 
marked deterioration of the general condition. 
2) Clinical examination with special stress on 
ascites, palpable hepatic masses, manifestation of 
liver cell failure, lower limb edema, chest and heart 
examination. 
3) Investigations: 
A) Laboratory investigation including: 
 CBC, ESR   
 Fasting and post prandial blood sugar.   
 Liver function tests: ALT, AST, GGT, ALP, 
Serum albumin, prothrombin time and 
concentration.  
 Tumor markers: AFP was done before therapy 
then 1&3 months after on this study and on follow 
up of the patients after one month and three 
months. 
B) Radiological investigations: 
 Plain X-ray of the chest.  
 Abdominal U/S. 
 Triphasic spiral CT. 
 The informations collected were evaluated using 
the previous imaging techniques; size, site and the 
vascularity of focal lesions.  
C) Histopathological examination: in one doubtful 
case an US guided biopsy from the hepatic focal 
lesion was used to confirm the diagnosis. 
The needles used for PAI were either 22-gauge 
non cutting needles (spinal needle; Becton-Dickinson, 
Rutherford, NJ) or 21-gauge needles with a closed 
conical tip and multiple terminal side holes 




      After each session, the patient was hospitalized 
for 72 hrs, if no complications occurred the patient 
was then discharged. During such a period, patients 
were closely observed with stress on vital signs, 
abdominal tenderness or rigidity. They also received 
prophylactic antibiotics, paracetamol tablets, and cold 
foments whenever the patients were feverish together 
with plenty of fluids intake.  
Post Treatment Assessment: 
All patients were subjected to the following measures, 
1 & 3 months after treatment: 
A- Full clinical examination. 
B- Laboratory investigations: 
1- Liver function tests (bilirubin, AST, ALT, alkaline 
phosphates, albumin and GGT)  
2- Renal function tests. 3- Alpha fetoprotein and 
CEA.  
C- Abdominal U/S.    
 D-Triphasic spiral CT. 
       Analysis of data was done by IBM computer 










(n=15) X2 test P- value 
No No 
Accidentally discovered 6(40.0%) 7 (46.7%) 0.136 0.713 (NS) 
Pain 6 (40.0%)  7 (46.7%)    0.136 0.713 (NS) 
Easy fatigability  4 (26.7%) 6 (40.0%) 2.22 0.136(NS) 
Anorexia 2 (13.3%) 4 (26.7%) 0.833 0.361(NS) 
Weight loss  5(33.3%) 4 (26.7%) 1.29 0.265(NS) 
Fever 1(6.7%) 1 (6.7%) 0.000 1.000(NS) 
Bleeding tendency 2 (13.3%) 0 (0%) 2.14 0.143(NS) 
Abdominal distension 2(13.3%) 1 (6.7%) 1.03 0.309(NS) 
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Table (2) Clinical  Examination of the patients: 
ITEM PAI group (n=15) RFA+PAIgroup   (n=15)  
X
2 
test P- value 
GENERAL EXAMINATION: 
Pallor 7 (46.7%) 6 (40%) 0.136 0.713 (NS) 
Jaundice 1 (6.7%) 1 (6.7%) 0.000 1.000 (NS) 
Palmar erythema 3 (20.0%) 4 (26.7%) 0.186 0.666(NS) 
Spider naevi 1 (6.7%) 1 (6.7%) 0.000 1.000 (NS) 
Lower limb edema 1 (6.7%) 1 (6.7%) 0.000 1.000 (NS) 
ABDOIMNAL EXAMINATION: 
Liver size: 



























1. Average size. 
2. Enlarged  
 
4 (26.7%) 
11 (73.3%)   
  
5 (33.3%) 
 10 (66.7%)  
0.000 0.690(NS) 
No statistical difference between the studied groups regarding the clinical examination. 
 
Table (3) Child’s classification among studied groups: 
 
Child classification Group Total X
2
 test  P-value 
 PAI  RFA+PAI  







Child B 4 (26.7%) 3 (33.3%) 7(100%) 
Child C 0 0 0 (0%) 
Total  15 (50%) 15 (50%) 30 100%) 
There was no statistical significant difference in the Child`s classification between the studied groups and our study not included 
Child`s C classification (one of exclusion criteria). 
 
Table (4) Comparison between the studied groups as regard liver profile before therapy: 
p-value t  test RFA+PAI group(n=15) PAI group(n=15) Variables 
0.987(NS) 0.112 78.8+18.5 75.10+10.63 ALT (IU) 
0.175(NS) 1.23 80.25+ 19.5 91.5+22 AST (IU) 
0.162(NS) 1.8 2.12+ 0.36 1.6+0.58 Bilirubin (mg/dl) 
0.286(NS) 1.1 121+17 120+12 Alkaline Phosphtase 
0.113(NS) 1.6 70+4.5 78.8+8.5 Prothrombin conc.   
There was no statistically significant difference in liver profile before therapy between the studied groups. 
 
Table (5 Comparison between the studied groups as regard tumour markers before therapy: 
p-value t  test RFA+PAI    group (n=15) PAI group  (n=15) Variable 
0.383 (NS) 0.886 566.4+201.5 552.1+235.8 AFP (ng/ml) 
No statistically significant difference between the studied groups as regard AFP before therapy ( p-value ˃ 0.05). 
 
Table (6) Focal lesions as detected by US in the patient groups: 
P-Value X
2

































0.904(NS)   0.202  
 
 8 (53.3%) = G 2a 
  7 (46.7%) =G 2b 
 
7 (46.7%)= G 1a 
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Each patient had only one focal lesion; most of them were hypoechoic in the Rt. Lobe of the liver. No statistical significant 
difference between the studied groups. 
 
Table (7) Liver profile  before and after treatment in group1: 
P-value t-test After 3 month P-value t-test After 1month Before TTT Variables 
 0.565(NS)  0.59 75.2+10.2 0.002(S)   3.8   84.5+8.61 75.2+11.03 ALT 
0.286 (NS) 1.10 72.2+14.7 0.000(S) 5.07 82.4+19.05 67.0+19.0 AST 
0.053(S) 2.1 1.45+.373 0.063(S) 2.01 1.51+0.443 1.6+0.58 Bilirubin (mg/dl) 
0.59(NS) 0.548 124.3+19.6 0.16(NS) 1.45 0.053+13.7 118.8+17.3 ALP 
0.001(S) 0.042 3.58+.322 0.041(S) 2.23   3.47+.363  3.28+.307 Albumin gm/dl 
   0.001(S)   4.49  8.07+7.93   0.003(S)   3.5   2.40+6.12 70.1+6.03 Proth  Conc. 
This table shows statistical significant change in liver enzymes, prothrombin and bilirubin levels before and after 1 &3 months of 
treatment (p-value less than 0.05). 
 
Table (8) Liver profile  before and after treatment in group 2: 
P-vlaue   t-test After 3 month P- value t-test After 1month Before TTT Variables 
0.267(NS) 1.22 78.1+11.5 0.001(S) 5.85 86.7+9.2 78.1+15.8 ALT 
0.285(NS) 1.21 72.6+12.5 0.003(S) 3.43 89.3 +31.6 83.2+29.5 AST 
0.147(NS) 1.24 1.35+0.29 0.29(NS) 1.25 1.8+0.50 2.12+ 0.36 S. bilirubin (mg/dl) 
0.160(NS) 1.48 142.6+44.58 0.02 (S) 2.58 150.2+45.6 130.8+36.2 ALP 
0.001(S) 4.38 3.86+0.36 00.01 (S)  2.84 3.7+0.36 3.1+1.45 S.albumin (gm/dl) 
0.002(S) 5.01 79.2+5.26 0.027(S) 2.82 78.5+9.2 73.5+6.9 Prothrombin Conc. 
Liver enzymes, prothrombin concentration and albumin have significantly improved 1 &3 months after treatment (p-value less 
than 0.05). 
 
Table (9) AFP (ng/ml) before and after treatment in group 1: 
P-value t test After 3 months   P-value t test After 1 month Before TTT Variables 
0.001(HS) 5.11 214.8+234.1  0.02(S) 2.41  311.2+163  552.1+235.8        AFP  
This table shows a highly significant decrease in AFP in group 1 after 1 & 3 months of treatment 
 
Table (10) AFP (ng/ml) before and after treatment in group 2: 
P-value t-test After3 months P-value t-test After 1 month BeforeTTT Variables 
0.001(HS) 0.67 137.3+88.11 0.001(HS) 3.91 226.11+154.3 566.4+201.5 AFP 
This table shows a highly significant decrease in AFP in group 2 after 1 & 3 months of treatment. 
 
Table (11) AFP (ng/ml) after 1 month of follow up: 
P-value t test RFA+PAI group(N=15) PAI group (N =15) Variables 
  0.03(S) 3.62 226.11+154.3   311.2+163  AFP 
This table shows that AFP has decreased significantly to lower levels in group 2 after 1 month.  
 
Table (12) AFP (ng/ml) after 3 month of follow up:  
P-value t test RFA+PAI group(N=15) PAI group(N=15)   Variables  
0.02(S)  3.30  137.3+88.11  214.8+234.1    AFP  
This table shows that AFP has decreased significantly to lower levels in group 2 after 3 month (p-value less than 0.05). 
 
Table (13) Changes in US after procedure in both groups (one week after procedure):   
ITEM PAI group (NO of FL=15) RFA+PAI group (NO of FL=15) X2 test   P- VALUE 
Number of FL: 
Same number  










































There was no statistical significant difference in the US findings after 1 week of the procedure in both groups. 
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Table (14) results of ablation in both groups: 
ITEM PAI group (NO of) FL=15 RFA+PAI group (NO of FL=15) X2test P –VALUE 













Complete ablation was achieved in 20 % & in 46.6 % of group1 & group2 respectively. The difference was highly significant. 
 
Table (15): Results of ablation in the subgroups(a =5-6.5 cm & b = 6.6-8 cm): 
ITEM PAI group (NO of FL=15)  RFA+PAI group (NO of FL=15)  X2test P –VALUE 
 G 1a=7 G 1b=8   Total G 2a=8 G 2b=7     Total     




















Complete ablation was achieved in 28.5% VS 62.5% of subgroups a, 12.5% VS 28.8% subgroups b with significant difference 
between the 2 groups.  
 
Table (16) comparison between the different subgroups after ablation: 
 Subgroups a   Subgroups b   
 G 1a=7 G 2a=8 X2test P -VALUE G 1b=8 G 2b=7 X2test P-VALUE 















Comparing subgroups 1a Vs 2a & 1b Vs 2b complete ablation was better in 1a & 2a due to the smaller sizes of the lesions. 
 
Table (17) Changes in sizes of the tumours after 3 months of procedure in both groups: 
ITEM PAI group (NO of FL=15)  RFA+PAI group (NO of FL=15)  X2test P –VALUE 
 G 1a=7 G 1b=8 Total G 2a=8 G 2b=7 Total   
















The diameter remained the same in 12(80%) of group 1 and 11(73.3%) of group 2 and increased in 3(20%) patients in group 1 and 
in 4(26.6%) of group 2. No significant difference between the 2 groups. 
 
Table (19 Procedure related complications in both groups: 
ITEM PAI group (N=15) RFA+PAI group (N=15) X2 test P –VALUE 
 Transient  pain 13 (86.7%) 11 (73.3%) 1.766 0.189(NS) 
Fever 2 (13.3%) 2(13.3%) 0.000 1.000(NS) 
PV thrombosis 0 (0%) 1 (6.7%) 1.034 0.320(NS) 
Ascites 0 (0%) 0 (0%) 0.000 1.000(NS) 
The transient pain and fever were more common complications 
 
4. Disscution 
         Hepatocellular carcinoma is a global 
dilemma (Di Bisceglie, 2002). Its incidence is rising 
in Egypt. Screening for HCC, particularly in cirrhotic 
patients or those with chronic HBV, is very important 
to discover it early. Surgical resection could be 
successful if the lesion is small, confined to one lobe 
in patients with extremely well preserved liver 
function (Llovet & Beaugrand, 2003) 
        Radio Frequency Thermal Ablation (RFA) is 
a local ablation technique designed to destroy the 
tumor by heating, in patients with unresectable liver 
tumors. The technique is save and effective (Azab et 
al., 2007 & 2008). Most of the Egyptian studies dealt 
with lesions ≤ 7 cm in diameter (Tabashy, 2004, 
Darweesh , 2005, El Shahawy , 2005 and Mohey , 
2007) 
       Percutaneous acetic acid injection (PAI) may 
have good penetration into cancer cells in the tumor 
capsule or intratumoral septa. (Okada, 1999) and it is 
better than ethanol in this respect (Azab et al., 2009) 
           The aim of the current study is to evaluate the 
efficacy of PAI if used alone or combined with RFA 
for the management of large tumours ranging from 5-
8 cm in diameter. The study included 30 patients with 
liver cirrhosis and documented HCC by Ultrasound 
and Triphasic CT scanning  AFP levels ≥ 
200ng/ml. They were randomly assigned to 2 groups, 
each group was subdivided into 2 subgroups 
according to the size of the tumor, Group 1a:-included 
7 patients (5-6.5 cm in diameter) managed by 2-3 
sessions of PAI only, 1 weeks apart. Group 1b:-
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included 8 patients (6.6-8 cm) managed by 2-3 
sessions of PAI only, 1weeks apart. Group 2a:-
included 8 patients (5-5.6 cm) treated by one setting 
of RFA using RF needle with that expand on 
deployment up to 5 cm in diameter plus 2-3 sessions 
PAI 2 weeks apart.Group2b:- included7 patients (6.6-
8 cm) treated by one setting of RFA using RF needle 
with that expand on deployment up to 5 cm in 
diameter plus 2-3 sessions PAI 2 weeks apart. We 
didn’t use a group for RFA only because we used the 
needle with arrays that could expand to 5 cm in 
diameter only leaving the rest of the lesion without 
ablation.  
       In our study the most presenting complaint in 
both groups was right hypochondrial pain, being 
present in 40% of group 1 and 46.7% of group 2. This 
is consistent with what had been reported by 
Sherlock and Dooley (2002), to be suspected if a 
patient with liver cirrhosis develops right upper 
quadrant pain.  
     Ahmed et al. (2001) and Azab et al. (2009) 
reported right hypochondrial pain in 40-47% of cases 
and Haseeb,(2000) reported it in 68% of their 
patients.    
        On general examination, hepatomegaly was 
detected in 4(26.7%) in both groups. Splenomegaly 
was detected in 11(73.3%) of group 1 and in 
10(66.7%) of group2. Our results were in agreement 
with the results of the studies done by El-Kady et al. 
(2001), Darweesh, (2005), and Azab et al. (2007 & 
2009) . 
          According to the ultrasonographic assessment 
of the studied groups before treatment, cirrhotic 
picture was seen in 100% in both groups. This high 
association between cirrhosis and HCC is agreed 
upon by Haseeb (2000) Ahmed et al. (2001) and 
Azab et al. (2009) found that 23 out of 25 patients 
(92%) had liver cirrhosis. Rosen and Nagorney 
(1997) found that more than 75% of their patients 
with HCC have underlying cirrhosis.. A study done 
by Mabrouk (1997) on 34 Egyptian patients with 
HCC revealed that all had liver cirrhosis. 
            The size of the liver was average in 6(40%) 
patients of group 1 and in 5(33.3%) patients of group 
2, enlarged in 5(33.3%) of group 1 and in 4(26.7%) of 
group 2, and shrunken in 5(33.3%) patients in each 
group. Splenomegaly was detected in 11(73.3%) 
patients of each group. No ascites was detected. Our 
results were in agreement with El-Kady et al. (2001) 
and Darweesh (2005) studies.  
       In these study 13 (86.6%) patients of group 1 and 
12(80%) patients of group 2 had their focal lesions in 
the right lobe. This is in agreement with Haseeb 
(2000) who found 32 out of 42 lesions (76%) in the 
right lobe while a higher percent (95%) were reported 
by Ahmed et al. (2001). The fact that focal lesions 
are more frequent in the right lobe is supported by 
Rosen & Nagorney (1997). The focal lesions were 
hypoechoic in 13(86.7%) of group 1 and 12(80 %) of 
group2. Our results are in agreement with Salama et 
al. (2003) and Lencioni & Menu (1999) who found 
that HCC is hypoechoic in more than 80% of their 
patients. 
       The CBC, transaminases, Serum bilirubin, 
alkaline phosphatase, albumin and prothrombin time 
&concentration were performed before treatment to 
all patients in both groups and they were repeated 
after the procedure. Billirubin, albumin and 
prthrombin concentration have significantly improved 
when evaluated 1&3 month after the procedure. This 
is in agreement with Huang et al. (2001), Salama et 
al. (2003) and Darweesh et al. (2005). 
            Alpha feto-protein (AFP) was elevated in 
7(46.6%) & 8(53.3%) of group 1 & 2 respectively, 
ranging from 200-4500 ng/ml. The mean values for 
the 2 groups were 552.1+235.8 & 566.4+201.5 
respectively. It decreased significantly 1 & 3 months 
after the procedure. Previous studies by Azab et al. 
(2009) showed similar figures. Mohamed et al. 
(2000) found elevated AFP in 45.1% of his HCC 
patients. Abdl Ghafar et al., (2002) found that most 
cases (73.3%) presented with high levels (>100 
ng/ml). The cut off value of AFP is debated and 
ranges between 200 and 1000 ng/ ml with increasing 
specificity by increasing the cut off level (Abdel–
Hameid, 1998).  
        There was change in tumour echogenicity from 
hypo- or isoechoic to hyperechoic in 12(80%) of 
group 1 and 13(86.6%) of group 2      after 1 week of 
the procedure. This goes with Rossi et al. (2000) who 
confirmed that US appearance of HCC is modified 
after ablation. Usually hypoechoic & isoechoic HCC 
lesions become hyperechoic (Azab et al., 2009).  
        At the end of treatment the US outcome is not 
entirely reliable. For this reason we did not depend on 
US picture alone but sequential AFP measurement 
and triphasic spiral CT were done to evaluate the 
therapeutic effect. AFP was measured in patients with 
elevated levels 1&3 months after the procedure. AFP 
has a plasma half-life of 5 days and therefore reflects   
production of tumour cell mass (Brumm et al., 1989) 
and decreased significantly during the follow up 
period.   
       The diameter of the lesions after the procedure  
increased in 13 (86.6%)patients of group 1 in 
comparison to 14(93.3%) patients of group 2, 
remained the same in 5 (33.3%) of group 1  and 3 
(20%) of group 2. The increased diameter is due to 
the penetration of the surrounding tissues by acetic 
acid. This gives a safety margin for HCC (Azab et 
al., 2009) allowing necrosis of malignant cells that 
may be found in the capsule of the tumor.  
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        The spiral CT done before the procedure showed 
early enhancement of the lesions in the arterial phase 
& wash out in the delayed & venous phases in 100% 
of cases. Our results are in agreement with 
Darweesh. (2005) as he concluded that contrast 
enhanced spiral CT is currently the most sensitive test 
for managing thermal ablation for patients with HCC. 
         Complete ablation was achieved in 46.6% of the 
group treated by combining RFA & PAI compared to 
20% of the group treated by PAI alone. This is 
probably because PAI couldn’t spread completely to 
the periphery of the tumors espically the large ones. 
When we started by RFA it induced necrosis for the 
central part of the tumor about 5 cm in diameter or a 
little bit more according the expansion of the RF 
needle arrays. We believe that acetic acid when 
injected after this central necrosis it diffuses more 
easily to the periphery of the tumors causing necrosis 
of larger volumes of HCC. This could explain the 
better results when RFA is conducted before acetic 
acid. 
           RFA alone used for large tumors gave less 
favourable results as that seen the study of Livraghie 
et al. (2000) who used RFA for tumors 5.1-9.5 cm in 
diameter. Complete ablation was achieved in 25% of 
the tumors presumably of small sized lesions. This 
percent of ablation is comparable to that of our study 
when we used acetic acid alone, but starting by RFA 
complete ablation was achieved in 46.6% compared 
to the 25% that was achieved by RFA alone in 
Livraghie et al. (2000) Study. 
         Our results indicate that combined therapy could 
achieve better results in the smaller lesions (5-6.5 
cm), since complete ablation was detected in 62.5% 
of subgroup 2a compared to 28.5% of subgroup 1a 
with highly significant difference. Previous studies 
have shown the advantage of early detection of HCC 
because ablation in this situation will give better 
results. Azab et al. (2009) obtained good response in 
treating relatively small lesions (3-6 cm) by PAI 
(86.7%). In our study RFA caused necrosis of most of 
HCC mass around (5-6.5 cm). The periphery of the 
lesion with thickness less than 2 cm could then be 
perfused by acetic acid causing necrosis if most if not 
all the tumor mass, since 2 sitting were done for such 
small HCC . 
      The complications of the procedures were 
minimal in our study. No mortalities related to the 
technique in both groups. Transient abdominal pain 
during the sessions was the most encountered 
problem. The abdominal pain was sometimes 
associated with shoulder pain in focal lesions of the 
right lobe near the diaphragm that was relieved by I.V 
analgesics. Only few patients had transient fever 
which could be due to tissue necrosis that was 
relieved by antipyretics .Our results correspond to 
those recorded by Livraghi et al. (1999) Salama et 
al. (2003) and Azab et al. (2007). 
       In our study AFP proved to be of great value for 
the follow up of patients who have had elevated levels 
before the procedure. It decreased below the 
diagnostic levels in patients having full ablation, in 
group 1 from 552.1+235.8 to 311.2+163 & 
214.8+234.1, 1 and 3 months later and in group2  
from 566.4+201.5 to 226.11+154.3& 137.3+88.11, 
one and three months later. These results are in line 
with studies done by Rossi et al. (2000).  And Azab 
et al. (2007&2008)   
       On follow up of the cases after the procedures, 
liver enzymes ALT, AST, S.bilirubin and 
prothrombin concentration showed statistically 
significant improvement after 1 and 3 months of 
ablation. This is in line with the studies done by Azab 
et al., (2007 & 2008). This is probably due to the 
removal of the deleterious effect of the tumour on the 
surrounding tissues.  
        At last but not at least it is concluded that the 
combination therapy of RFA & PAI for large HCC 
lesions could induce good ablation in a proportion of 
the patients & partial ablation in the rest which might 




From this study we recommend the following: 
1-Screening for HCC by US and AFP periodically in 
high risk patients like chirrotics and HBV, every 3 
months is important to detect small lesions, it could 
be then surgically resectable or completely ablated. 
2-If accidentally discovered and was large (up to 8 cm 
in diameter), a reasonable percentage of patients 
could benefit from percutaneous ablation modalities, 
either single or in combination, like what have been 
done in our study. 
3-The development of RFA with larger diameters (e.g 
7 cm) could be a useful tool for large tumors giving 
better results than the 5 cm used in this study. 
4-Combination of different modalities is in need to be 
evaluated to test which combination gives the best 
results. 
5-The higher the number of patients included in such 
studies the more precise information about the best 
modalities could be collected. 
6-Larger periods of follow up for such patients to 
evaluate the recurrence at the site of the tumor or 
development of lesions at other sites and the effect on 
survival of patient are needed. 
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